Clinical trial
MCLENA-1: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Lenalidomide in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease
NCT04032626 is registered in ClinicalTrials.gov with St. Joseph's Hospital and Medical Center, Phoenix as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- MCLENA-1: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Lenalidomide in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease
- Lead sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 22, 2020
- Completion date
- May 31, 2025
- Enrollment
- 15 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
amyloid plaque, cognitive dysfunction, cognitive impairment, mild, inflammation, brain, neurodegeneration